Saturday 17 October 2026
Export LFCR’s income statement to Excel — free account
Lifecore Biomedical, Inc.
LFCR Healthcare Drug Manufacturers Specialty & Generic
In the quarter to June 2026, revenue fell 6.25%, EPS fell 216.7%, free cash flow fell 117.0% and total debt rose 15.3%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
6.38
0.06
−0.93%
Follow LFCR
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | — | 0.00 |
+8 more quarters Free account |
P/S ratio |
1.65 | 1.14 | — | 2.21 | |
P/FCF ratio |
0.00 | 10.32 | — | 20.90 | |
P/Operating CF |
(90.12) | 29.66 | — | (57.52) | |
P/B ratio |
0.00 | 0.00 | — | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | — | 0.00 | |
EV/Sales |
3.06 | 2.19 | — | 3.35 | |
EV/EBITDA |
0.00 | 0.00 | — | 0.00 | |
EV/Operating CF |
(713.10) | 19.39 | — | 28.96 | |
EV/FCF |
(72.23) | 19.79 | — | 31.71 | |
Quick Ratio |
2.20 | 1.96 | 1.85 | 1.46 | |
Current Ratio |
3.87 | 3.79 | 3.49 | 2.80 | |
Net Debt/EBITDA |
33.01 | (53.76) | 0.00 | (27.90) | |
Debt/Assets |
80.62% | 65.53% | 72.29% | 68.24% | |
Debt/Equity |
11.50 | 7.11 | 4.93 | 4.36 | |
Asset Turnover |
0.51 | 0.52 | 0.00 | 0.51 | |
Operating CF/Net income |
0.31 | (0.29) | — | 0.44 | |
Capex/Depreciation |
(0.20) | (0.48) | — | 0.59 | |
Interest Coverage |
0.33 | (0.64) | — | (0.48) | |
Research and Development Expense of Revenue |
4.50% | 5.25% | — | 6.31% | |
Selling, General and Administrative Expense of Revenue |
23.33% | 34.14% | — | 28.59% | |
Intangible Assets out of Total Assets |
0.06 | 0.06 | 0.06 | 0.08 | |
Share Based Compensation of Revenue |
6.10% | 7.32% | — | (6.35%) | |
Graham Net Nets |
(0.66) | (0.91) | — | (0.42) | |
Graham Number |
4.45 | 3.79 | — | 2.36 | |
Earnings Yield |
(18.48%) | (22.58%) | — | (11.96%) | |
Free Cash Flow Yield |
(2.57%) | 9.69% | — | 4.78% | |
Revenue per Share |
0.91 | 0.62 | — | 0.83 | |
Operating CF per Share |
(0.06) | 0.13 | — | (0.13) | |
Capex per Share |
(0.01) | (0.03) | — | (0.03) | |
Free Cash Flow per Share |
(0.07) | 0.10 | — | (0.16) | |
Cash per Share |
0.46 | 0.55 | 0.00 | 0.50 | |
Shareholders Equity per Share |
0.43 | 0.55 | 0.00 | 0.98 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.43 | 0.55 | 0.00 | 0.98 | |
Free Cash Flow |
(2.70) | 3.58 | — | (5.97) | |
Working Capital |
62.05 | 57.14 | 58.72 | 53.97 | |
Capital Expenditures |
(0.51) | (1.12) | — | (1.18) | |
Net Current Asset Value |
(129.72) | (127.08) | (115.82) | (114.49) | |
EV/EBIT |
0.00 | 0.00 | — | 92.41 | |
Capex to Sales |
0.02 | 0.05 | — | 0.04 | |
Price to Operating Income |
0.00 | 0.00 | — | 0.00 | |
| Other line items | |||||
Average Receivables |
27.60 | 24.06 | 26.83 | 27.53 | |
Average Payables |
8.82 | 7.62 | 6.81 | 12.54 | |
Average Inventory |
29.64 | 30.22 | 31.84 | 36.51 | |
Average Assets |
232.35 | 232.42 | 234.94 | 245.30 | |
Average Common Equity |
(22.32) | (13.55) | (5.99) | 2.46 |
Columns are period end dates